AbbVie Inc vs HP Inc — how do they compare? AbbVie Inc trades at $248.69 (market cap $441.94B), while HP Inc trades at $29.2 (market cap $26.59B). The key difference: AbbVie Inc is far larger — about 16.6× HP Inc's market cap, and HP Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| ABBV | HPQ | |
|---|---|---|
Market Cap | $441.94B | $26.59B |
Sector | Health | Technology |
52-Week High | $263.58 | $30.05 |
52-Week Low | $197.38 | $18.20 |
Enterprise Value | $506.19B | $33.75B |
Dividend Yield | 2.77% | 4.13% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.
Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.
HPQ trades at $28.96, down 2.82% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue for 2025 reached $55.3 billion, with a net income margin of 4.45%, while valuation metrics like a P/E of 10.77 and P/S of 0.48 suggest potential undervaluation. Recent news highlights AI-driven cost savings and a profitable upgrade cycle, with Q2 FY2026 revenue up 9% year-over-year.
The outlook is mixed; HPQ benefits from solid cash flow and dividend yields near 4%, but faces risks from PC market declines and competitive pressures. Analyst consensus is cautious with a hold-heavy rating, and the stock trades above the consensus price target of $22, indicating limited upside. Investors should weigh steady profitability against industry headwinds and valuation constraints.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →